In some people, the body’s mechanism for cooling itself is overactive — so overactive that they may sweat four or five times more than is necessary, or normal. When sweating is this extreme it can be embarrassing, uncomfortable, anxiety-inducing, dangerous, and disabling. It often disrupts all aspects of a person's life, from career choices and recreational activities to relationships, emotional well-being, and self-confidence. This kind of excessive sweating is a serious medical condition. It's called hyperhidrosis and it afflicts millions of people around the world (nearly 5% of the world's population). But, due to lack of awareness among sufferers and lack of education among medical professionals, most people are never diagnosed or relieved of their symptoms.
The global market for Hyperhidrosis Treatment was estimated to be worth US$ 1302 million in 2023 and is forecast to a readjusted size of US$ 1921.1 million by 2030 with a CAGR of 5.5% during the forecast period 2024-2030
Global top 5 players of hyperhidrosis treatment include Allergan (AbbVie), GlaxoSmithKline, Cynosure, Journey Medical Corporation and miraDry. As the largest player, Allergan (AbbVie) makes up over a quarter.
North America ranks first in terms of market size by region, making up around 35%, followed by Europe and Asia-Pacific.
Based on the product type, the hyperhidrosis treatment is primarily split into medications, surgical treatments and physiotherapy, etc. Among them, medical is the largest segment, with a share over 45%.
Hyperhidrosis treatment is mainly used for primary focal hyperhidrosis and secondary generalized hyperhidrosis, in which the former one dominates with a share over 60%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hyperhidrosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hyperhidrosis Treatment by region & country, by Type, and by Application.
The Hyperhidrosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperhidrosis Treatment.
Market Segmentation
By Company
Allergan (AbbVie)
GlaxoSmithKline
Cynosure
Journey Medical Corporation
miraDry
Alma Lasers
Carpe
Duradry
Merz Ultherapy
Fotona
BTXA
Seaford Pharmaceuticals
Robugen GmbH
Segment by Type:
Medications
Surgical Treatments
Physiotherapy
Segment by Application
Primary Focal Hyperhidrosis
Secondary Generalized Hyperhidrosis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hyperhidrosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Hyperhidrosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Hyperhidrosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Hyperhidrosis Treatment Product Introduction
1.2 Global Hyperhidrosis Treatment Market Size Forecast
1.3 Hyperhidrosis Treatment Market Trends & Drivers
1.3.1 Hyperhidrosis Treatment Industry Trends
1.3.2 Hyperhidrosis Treatment Market Drivers & Opportunity
1.3.3 Hyperhidrosis Treatment Market Challenges
1.3.4 Hyperhidrosis Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hyperhidrosis Treatment Players Revenue Ranking (2023)
2.2 Global Hyperhidrosis Treatment Revenue by Company (2019-2024)
2.3 Key Companies Hyperhidrosis Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Hyperhidrosis Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Hyperhidrosis Treatment
2.6 Hyperhidrosis Treatment Market Competitive Analysis
2.6.1 Hyperhidrosis Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Hyperhidrosis Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperhidrosis Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Medications
3.1.2 Surgical Treatments
3.1.3 Physiotherapy
3.2 Global Hyperhidrosis Treatment Sales Value by Type
3.2.1 Global Hyperhidrosis Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Hyperhidrosis Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Hyperhidrosis Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Primary Focal Hyperhidrosis
4.1.2 Secondary Generalized Hyperhidrosis
4.2 Global Hyperhidrosis Treatment Sales Value by Application
4.2.1 Global Hyperhidrosis Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Hyperhidrosis Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Hyperhidrosis Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Hyperhidrosis Treatment Sales Value by Region
5.1.1 Global Hyperhidrosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Hyperhidrosis Treatment Sales Value by Region (2019-2024)
5.1.3 Global Hyperhidrosis Treatment Sales Value by Region (2025-2030)
5.1.4 Global Hyperhidrosis Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Hyperhidrosis Treatment Sales Value, 2019-2030
5.2.2 North America Hyperhidrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Hyperhidrosis Treatment Sales Value, 2019-2030
5.3.2 Europe Hyperhidrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Hyperhidrosis Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Hyperhidrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Hyperhidrosis Treatment Sales Value, 2019-2030
5.5.2 South America Hyperhidrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Hyperhidrosis Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Hyperhidrosis Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hyperhidrosis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Hyperhidrosis Treatment Sales Value
6.3 United States
6.3.1 United States Hyperhidrosis Treatment Sales Value, 2019-2030
6.3.2 United States Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Hyperhidrosis Treatment Sales Value, 2019-2030
6.4.2 Europe Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Hyperhidrosis Treatment Sales Value, 2019-2030
6.5.2 China Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Hyperhidrosis Treatment Sales Value, 2019-2030
6.6.2 Japan Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Hyperhidrosis Treatment Sales Value, 2019-2030
6.7.2 South Korea Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Hyperhidrosis Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Hyperhidrosis Treatment Sales Value, 2019-2030
6.9.2 India Hyperhidrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Hyperhidrosis Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Allergan (AbbVie)
7.1.1 Allergan (AbbVie) Profile
7.1.2 Allergan (AbbVie) Main Business
7.1.3 Allergan (AbbVie) Hyperhidrosis Treatment Products, Services and Solutions
7.1.4 Allergan (AbbVie) Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Allergan (AbbVie) Recent Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Profile
7.2.2 GlaxoSmithKline Main Business
7.2.3 GlaxoSmithKline Hyperhidrosis Treatment Products, Services and Solutions
7.2.4 GlaxoSmithKline Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 GlaxoSmithKline Recent Developments
7.3 Cynosure
7.3.1 Cynosure Profile
7.3.2 Cynosure Main Business
7.3.3 Cynosure Hyperhidrosis Treatment Products, Services and Solutions
7.3.4 Cynosure Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Journey Medical Corporation Recent Developments
7.4 Journey Medical Corporation
7.4.1 Journey Medical Corporation Profile
7.4.2 Journey Medical Corporation Main Business
7.4.3 Journey Medical Corporation Hyperhidrosis Treatment Products, Services and Solutions
7.4.4 Journey Medical Corporation Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Journey Medical Corporation Recent Developments
7.5 miraDry
7.5.1 miraDry Profile
7.5.2 miraDry Main Business
7.5.3 miraDry Hyperhidrosis Treatment Products, Services and Solutions
7.5.4 miraDry Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 miraDry Recent Developments
7.6 Alma Lasers
7.6.1 Alma Lasers Profile
7.6.2 Alma Lasers Main Business
7.6.3 Alma Lasers Hyperhidrosis Treatment Products, Services and Solutions
7.6.4 Alma Lasers Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Alma Lasers Recent Developments
7.7 Carpe
7.7.1 Carpe Profile
7.7.2 Carpe Main Business
7.7.3 Carpe Hyperhidrosis Treatment Products, Services and Solutions
7.7.4 Carpe Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Carpe Recent Developments
7.8 Duradry
7.8.1 Duradry Profile
7.8.2 Duradry Main Business
7.8.3 Duradry Hyperhidrosis Treatment Products, Services and Solutions
7.8.4 Duradry Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Duradry Recent Developments
7.9 Merz Ultherapy
7.9.1 Merz Ultherapy Profile
7.9.2 Merz Ultherapy Main Business
7.9.3 Merz Ultherapy Hyperhidrosis Treatment Products, Services and Solutions
7.9.4 Merz Ultherapy Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Merz Ultherapy Recent Developments
7.10 Fotona
7.10.1 Fotona Profile
7.10.2 Fotona Main Business
7.10.3 Fotona Hyperhidrosis Treatment Products, Services and Solutions
7.10.4 Fotona Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Fotona Recent Developments
7.11 BTXA
7.11.1 BTXA Profile
7.11.2 BTXA Main Business
7.11.3 BTXA Hyperhidrosis Treatment Products, Services and Solutions
7.11.4 BTXA Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 BTXA Recent Developments
7.12 Seaford Pharmaceuticals
7.12.1 Seaford Pharmaceuticals Profile
7.12.2 Seaford Pharmaceuticals Main Business
7.12.3 Seaford Pharmaceuticals Hyperhidrosis Treatment Products, Services and Solutions
7.12.4 Seaford Pharmaceuticals Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Seaford Pharmaceuticals Recent Developments
7.13 Robugen GmbH
7.13.1 Robugen GmbH Profile
7.13.2 Robugen GmbH Main Business
7.13.3 Robugen GmbH Hyperhidrosis Treatment Products, Services and Solutions
7.13.4 Robugen GmbH Hyperhidrosis Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Robugen GmbH Recent Developments
8 Industry Chain Analysis
8.1 Hyperhidrosis Treatment Industrial Chain
8.2 Hyperhidrosis Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hyperhidrosis Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Hyperhidrosis Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Allergan (AbbVie)
GlaxoSmithKline
Cynosure
Journey Medical Corporation
miraDry
Alma Lasers
Carpe
Duradry
Merz Ultherapy
Fotona
BTXA
Seaford Pharmaceuticals
Robugen GmbH
*If Applicable.